Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes

  • Authors:
    • Lei Xia
    • Dianxuan Guo
    • Bing Chen
  • View Affiliations

  • Published online on: September 29, 2017     https://doi.org/10.3892/etm.2017.5238
  • Pages:5569-5575
0

Abstract

Parkinson's disease (PD) is characterized by a progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta. Inflammation and neural degeneration are implicated in the pathogenesis of PD. Astragaloside IV (AS‑IV) has been verified to attenuate inflammation. The current study aimed to investigate the role of AS‑IV in PD and the possible molecular mechanisms. Pole, traction and swim tests were performed to examine the effects of AS‑IV on 1‑methyl‑4‑phenyl‑1, 2, 3, 6‑tetrahydropyridine (MPTP)‑generated behavioral deficiencies in vivo. Meanwhile, as for in vitro experiments, the influence of AS‑IV on cell viability was evaluated using the 3‑(4, 5‑dimethyl‑2‑thiazolyl)‑2, 5‑diphenyl‑2‑H‑tetrazolium bromide (MTT) assay, the effects of AS‑IV on 1‑methyl‑4‑phenylpyridnium ion (MPP+)‑induced cell viability changes were tested using MTT assays, cell apoptosis rates were assessed using an Annexin‑V Fluorescein isothiocyanate kit, and the expression levels of phosphorylated‑Jun N‑terminal kinase (p‑JNK), Bcl‑2‑associated X protein (Bax)/Bcl‑2 and caspase‑3 activity were assessed using western blot analysis. Behavioral tests showed that pretreatment of AS‑IV significantly alleviated MPTP‑generated behavioral deficiencies in vivo. Meanwhile, AS‑IV remarkably rescued MPP+‑induced cell viability reduction, increase in cell apoptosis rate, and upregulation of p‑JNK, Bax/Bcl‑2 ratio and caspase‑3 activity in vitro. In conclusion, AS‑IV may be a promising neuroprotective agent for PD.

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

2016 Impact Factor: 1.261
Ranked #50/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Xia, L., Guo, D., & Chen, B. (2017). Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes. Experimental and Therapeutic Medicine, 14, 5569-5575. https://doi.org/10.3892/etm.2017.5238
MLA
Xia, L., Guo, D., Chen, B."Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes". Experimental and Therapeutic Medicine 14.6 (2017): 5569-5575.
Chicago
Xia, L., Guo, D., Chen, B."Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes". Experimental and Therapeutic Medicine 14, no. 6 (2017): 5569-5575. https://doi.org/10.3892/etm.2017.5238